Clinical Trials

JBCRG-18Cape

Phase I Clinical Study of Combination Therapy with Eribulin and Capecitabine in Patients with Progressive Recurring Breast Cancer(JBCRG-18Cape)

Status
Study Closed

Objectives
In this clinical study, the maximum tolerated dose (MTD) will be estimated, based on the dose limiting toxicity of the combination therapy of eribulin (HAL) and capecitabine (X) in patients with progressive recurring breast cancer, and the recommended dose (RD) for Phase II clinical study will be determined.

Subjects

Endpoints
Primary endpoints: MTD, DLT, RD Secodary endpoints: AE, ORR, PK

Trial Period
Dec.2012 to Nov.2014

Lead Principal Investigator
Hiroji Iwata (Dept. of Breast Oncology, Aichi Cancer Center Hospital)

Target Sample Size
6-18

Regimen
Combined therapy of Eribulin and Capecitabine

Source of Funding
JBCRG (Japan Breast Cancer Research Group)

Conference Presentation
Phase Ib dose-escalation study of eribulin plus capecitabine in metastatic breast cancer (JBCRG-18Cape)

Articles and Publications

UMIN-ID
UMIN000009611

jRCT

Memo

COI Disclosure

Previous PageClinical TrialsNext Page